PortViewPortView
Check-Cap logo

Check-Cap (MBAI) Stock Analysis

NASDAQHealthcareMedical - Diagnostics & Research

$6.42-2.21%
1-year price historyRange $6.30 – $22.12
52-week range$6.42
$4.41$27.44

What Check-Cap does

Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.

Key metrics

Market cap
$6.43M
P/E (TTM)
9.57
EPS (TTM)
$0.67
Beta
0.82
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$7.98
200-day avg
$10.80
52-week high
$27.44
52-week low
$4.41
CEO
David Lontini

ETFs linked to MBAI

Broad-market and Healthcare sector ETFs an investor holding Check-Cap is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MBAI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze MBAI in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Check-Cap?
Check-Cap trades under the ticker MBAI on NASDAQ.
Which exchange is MBAI listed on?
MBAI is listed on NASDAQ.
What sector does Check-Cap operate in?
Check-Cap is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze MBAI in a portfolio?
PortView shows MBAI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.